Should we prescribe ursodeoxycholic acid after laparoscopic sleeve gastrectomy? A two-center prospective randomized controlled trial | ||
| The Egyptian Journal of Surgery | ||
| Volume 37, Issue 3, July 2018 PDF (351.59 K) | ||
| DOI: 10.4103/ejs.ejs_25_18 | ||
| Authors | ||
| Tarek A.O. Abouzeid; Ahmed A.A. Shoka | ||
| Abstract | ||
| Background In the recent era, laparoscopic sleeve gastrectomy (LSG) had emerged as a safe and effective bariatric procedure. Rapid weight loss is associated with deranged cholesterol metabolism in the form of gallstones. Materials and methods This two-center prospective randomized controlled trial had been conducted at Abha Private Hospital, Saudi Arabia, and Ain-Shams University hospitals, Egypt, from May 2016 to June 2017 on 89 post-LSG patients. After block randomization, patients were allocated into either group A (UDCA treatment) or group B (control). UDCA was prescribed as 250 mg twice daily for 12 months or until the development of gallstones. Results A total of 44 patients were included in group A and 45 patients were included in group B. There was no significant difference between both the groups regarding the baseline parameters. Conclusion UDCA is a safe prophylactic measure against gallstones formation and should be integrated into the post-LSG prescription. | ||
| Keywords | ||
| Cholelithiasis; gallstone prevention; Laparoscopic sleeve gastrectomy; postlaparoscopic sleeve complications; ursodeoxycholic acid | ||
|
Statistics Article View: 46 PDF Download: 36 |
||
